AGBL2 and systemic lupus erythematosus: However, anti-CCP2 has been demonstrated to be extremely specific (96–98%) in patients with RA [26], but only 13.8% with SLE, 2.6% with SSc [27] and 7.5–9% with pSS [28], [29].